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N E U R O - O N C O L O G Y
2013 WFNO-SNO Abstracts
SURGICAL THERAPIES
ST-001. PHASE 1 TRIAL OF A RETROVIRAL REPLICATING
VECTOR (TOCA 511) IN RECURRENT HIGH GRADE GLIOMA
PATIENTS DEMONSTRATES THE IMPORTANCE OF REAL-TIME
MRI-GUIDED DELIVERY FOR DOSE-RELATED EVALUATION OF
SAFETY AND EFFICACY
Manish Aghi1, Michael A. Vogelbaum2, Douglas J. Jolly3, Joan M. Robbins3,
Derek Ostertag3, Carlos E. Ibañez3, Harrry E. Gruber3, Noriyuki Kasahara4,
Krystof Bankiewicz5, Timothy F. Cloughesy6, Susan M. Chang5,
Nicholas Butowski5, Santosh Kesari7, Clark Chen7, Tom Mikkelsen8,
Joseph Landolfi9, E. Antonio Chiocca10,12, J. Bradley Elder10, Greg Foltz11,
and Dan Pertschuk3; 1Dept. of Neurological Surgery UCSF, San Francisco CA,
USA; 2Cleveland Clinic, Cleveland, OH, USA; 3Tocagen Inc., San Diego CA,
USA; 4Dept. of Medecine UCLA, Los Angeles CA, USA; 5Dept. of
Neurological Surgery UCSF, San Francisco CA, USA; 6Dept. of Neurology
UCLA, Los Angeles CA, USA; 7Moores Cancer Center UCSD, San Diego CA,
USA; 8Dept. of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA; 9John
F. Kennedy Medical Center, Edison NJ, USA; 10Dept. of Neurological Surgery
OSU Med Center, Columbus, OH, USA; 11Swedish Neuroscience Institute,
Seattle WA, USA; 12Dept. of Surgery Brigham and Womens Hospital, Boston
MA, USA
We are conducting investigational dose escalation trials in patients with
High Grade Glioma (HGG, NCT01156584 and NCT01470794), using a ret-
roviral replicating vector (Toca 511). Toca 511 (vocimagene amiretrorepvec)
encodes an optimized yeast cytosine deaminase that converts 5-fluorocytosine
(5-FC) to the anti-cancer drug 5-FU in infected tumors. We report here results
of aPhase1/2 trial of direct intratumoralToca511 administration to recurrent
HGG patients, followed by repeat courses of oral 5-FC. Six Toca 511 dose
levels, escalated by half logs, the mode of administration and the use of extend-
ed release 5-FC (Toca FC) were investigated in 25 HGG patients to date.
Treatment at all dose levels has been well tolerated. Post-treatment resection
in two patients showed viral protein and DNA and RNA sequences including
the CD gene, suggesting viral spread and persistence. MRI and clinical im-
provements were also occasionally observed. Virus was initially delivered
via a brain biopsy needle and placement in the tumor was predicted using con-
ventional neuro-navigation. Immediate MRI after injection of Toca 511
spiked with gadolinium showed inconsistent delivery of Toca 511 to tumors.
As a result, real-time MRI-guided delivery was introduced using Toca 511 in-
fusion with a stepped-tip cannula. Using this approach, delivery into as many
as 4 locations of up to 3 mL of Toca 511 at flow rates of up to 30 mL/min has
been achieved without reflux. In a tumor biopsy from a patient who received
1 mL of Toca 511 and subsequent Toca FC, we observed tumor selective
vector transduction and expression by PCR and RT-PCR with concomitant
tumor necrosis. At higher Toca 511 doses, significant MRI changes consistent
with tumor regression were observed post-Toca FC dosing. Completion of this
study is planned, including dose escalationof Toca511 and increasing the dose
and duration of Toca FC.
ST-002. ENDOSCOPIC PITUITARY TUMOR SURGERY: THE
LEARNING CURVE
Amjad Anaizi, Christopher Taylor, Jennifer Kosty, Lee Zimmer, and
Philip Theodosopoulos; University of Cincinnati, Cincinnati, OH, USA
INTRODUCTION: Endoscopic endonasal pituitary surgery is increasing
utilized and is being passed on to the next generation of neurosurgeons. This
approach can be technically challenging due to lack of 3 dimensional visuali-
zation, increased operativeworking distanceand novel/different instrumenta-
tion. We present our experience with the exclusive endoscopic endonasal
approach over the last 10 years. METHODS: We performed a retrospective
review of patients who underwent an endoscopic endonasal pituitary tumor
resection between 2003-2012 by a single neurosurgeon/ ENT surgeon team
(PT, LZ). We assessed the extent of resection based on comparison of pre
and post-operative imaging for each case. We reviewed complications includ-
ing post-operative hypopituitarism, diabetes insipidus and CSF leaks. We then
compared these outcome parameters in the first half of patients operated on
(group A) with the second half of patients (group B). RESULTS: A total of
240 patients with adequate follow up were included in the study. Average
patient age in both groups was 51 years. F:M ratio in both groups was
1.15:1. In Group A 55.8% had a GTR and 44.2% had a STR. In Group B,
59.2% had a GTR and 40.8% had a STR. The rate of new post-operative pi-
tuitary dysfunction was 18.3% in Group A and 15% in group B. The rate of
diabetes insipidus was 12.5% in group A and 3.3% in group B (P , 0.01).
The rate of post-operative CSF leaks was 3.3% in Group A and 2.5% in
group B. CONCLUSION: The 2 dimensional view, increased working dis-
tance and novel instrumentation can result in a steep learning curve for endo-
scopic pituitary surgery. Increased experience should result in improved
patient outcomes, particularly a decreased rate of diabetes insipidus.
ST-003. FACIAL NERVE PRESERVATION SURGERY FOR LARGE
VESTIBULAR SCHWANNOMAS: FUNCTIONAL AND TUMOR
CONTROL OUTCOMES
Amjad Anaizi, Eric Gantwerker, Myles Pensak, and Philip Theodosopoulos;
University of Cincinnati, Cincinnati, OH, USA
OBJECT: Large vestibular schwannomas pose a unique challenge of achiev-
ing surgical cure while maintaining normal facial nerve function. Facial nerve
preservation surgery, defined as attempted maintenance of normal facial nerve
function at the cost of residual tumor when adherent to the facial nerve or root
entry zone, is a novel idea. We present our experience and evaluate functional
outcomes and extent of resection. METHOD: We performed a retrospective
review of patients treated surgically by a single surgeon team (PVT, MP) for
large (Koos 3 & 4) vestibular schwannomas between 2003-2012. We review
the extent of resection, post-operative hearing and facial nerve function. We
separated the patients into groups based on extent of resection (gross total,
near-total and subtotal) and evaluated the tumor control rate and functional
outcome. RESULTS: A total of 56 patients were included in the study. Four pa-
tients had received radiation treatment to their tumors prior to surgery. 18 pa-
tients underwent a retrosigmoid and 38 underwent a translabyrinthine
approach. Hearing was preserved in 1 of 5 (20%) GTR patients, 0 of 2 NTR
patients and 1 of 3 (33%) STR patients. Good facial nerve function (HBI &
II) was achieved long term in 17 of 20 (85%) GTR patients, 11 of the 12
(92%) NTR patients and 22 of the 24 (92%) STR patients. Only the GTR
group had HB IV or worse facial nerve function (3 patients). Long term tumor-
control was 100% for GTR, 92% for NTR and 83% for STR. 9 STR patients
and 1 NTR patient received postoperative radiation therapy. Average
follow-up was 33 months. CONCLUSION: Facial nerve preservation
surgery is associated with increased chance of long term good facial nerve
outcome. The rate of tumor progression following STR is 17%.
ST-004. NASAL CAVITY MALIGNANCIES INVOLVING THE
SKULL BASE: IS THERE A ROLE FOR ENDOSCOPY?
Amjad Anaizi, Sanjeet Grewal, Philip Theodosopoulos, and Lee Zimmer;
University of Cincinnati, Cincinnati, OH, USA
OBJECT: The role of endoscopy in the resection of malignant lesions
remains controversial. Such malignancies are traditionally resected through
transfacial approaches and any skull base involvement is addressed through
transcranial or combined approaches. We present a series of patients with
nasal cavity malignancies involving the skull base treated with purely endo-
scopic or endoscopic-assisted resections and offer an algorithm to assist in
the appropriate selection of these patients. METHOD: We retrospectively re-
viewed the charts of patients with malignant nasal cavity lesions involving the
skull base resected utilizing nasal endoscopy. RESULTS: A total of 9 patients
were included in the series. M:F ratio was 3.5:1. Average age at time of surgery
was 52 years. Pathology included Esthesioneuroblastoma, sarcoma, SNUC,
melanoma, adenocarcinoma and myofibroblastic tumor. 2 patients (22%)
had intra-orbital extension and 1 patient (11%) had pterygopalatine or infra-
temporal fossa extension. All patients had skull base involvement, 5 (56%) of
which had intradural extension. 6 patients (67%) underwent a purely endo-
scopic resection and 3 patients (36%) had a combined approach. 6 (67%) pa-
tients had a GTR and 3 (33%) patients had subtotal resection. Average EBL
was 780 ml. 67% of patients retained olfaction post-op. Average follow-up
was 25 months. 6 (67%) underwent post-operative adjuvant treatment.
Complications included 2 post-op CSF leaks. CONCLUSION: Nasal cavity
malignancies involving the skull base can often be difficult to resect. Open
transfacial approaches are effective, but can be associated with significant
morbidity. We believe that endoscopic and endoscopic-assisted techniques
offer a minimally disruptive alternative for the management of many of
these lesions in appropriately selected patients.
Neuro-Oncology 15:iii217–iii225, 2013.
doi:10.1093/neuonc/not191
#The Author(s) 2013. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.













ST-005. SURGICAL RESECTION FOLLOWING PRIMARY
RADIATION TREATMENT FOR VESTIBULAR SCHWANNOMAS:
DOES RADIATION IMPACT SURGICAL OUTCOMES AND
EXTENT OF RESECTION?
Amjad Anaizi, Myles Pensak, and Philip Theodosopoulos; University of
Cincinnati, Cincinnati, OH, USA
OBJECTIVE: With the advent of highly focused delivery of radiation, an in-
creasing number of vestibular schwannomas are being treated this way. A mi-
nority of these patients will fail this management strategy and require
subsequent treatment. Early studies have shown poor post-operative facial
function pressumably due to radiation-induced fibrosis and adhesions to sur-
rounding neurovascular structures. We present our experience with salvage
surgical procedures following failed primary radiation treatment for vestibu-
lar schwannomas. METHODS: We performed a retrospective review of pa-
tients with unilateral vestibular schwannomas who underwent resection
following failed primary radiation treatment. No patient had prior surgery
for the same lesion and NF2 patients were excluded. We present patient demo-
graphic information, preoperative radiation treatment modality and preoper-
ative facial nerve function. We review operative approach, pathology, extent
of resection, facial nerve function, tumor control and complications.
RESULTS:5patientswith vestibular schwannomaspreviously treated with ra-
diation underwent surgical resection. 3 patients received prior SRS and 2 pa-
tients received prior fractionated radiotherapy. Average time between
radiation and surgery was 42 months. No patients had serviceable hearing
prior to surgery. All patients underwent a translabyrinthine approach. A
gross total resection was achieved in 4 patients (80%), and a subtotal resection
in 1 patient (20%). 3 patients (60%) had a good (HBI & II) post-operative
facial nerve outcome. 2 patients had a HB IV facial nerve palsy. Pathology re-
vealed WHO I vestibular schwannoma in all patients. No patient had post-
operative tumor progression with an average of 27 months follow up.
CONCLUSION: Vestibular schwannomas that have failed primary radiation
can present a difficult treatment dilemma to the surgeon. Although radiation
effects can increase the potential for post-operative cranial nerve dysfunction
and decrease the likelihood of achieving gross total resection, surgical resec-
tion with modern surgical technique is a safer and more effective than what
earlier data would suggest.
ST-006. ENDOSCOPIC SURGERY FOR INTRAVENTRICULAR
AND PARAVENTRICULAR TUMORS
Yoshiki Arakawa1, Yoo Kang2, Daiki Murata1, Ko-ichi Fujimoto1, and
Susumu Miyamoto1; 1Department of Neurosurgery, Kyoto University
Graduate School of Medicine, Kyoto, Japan; 2Department of Neurosurgery,
Ohno Memorial Hospital, Osaka, Japan
BACKGROUND: Endoscopic management for the ventricular lesions has
been widely applicable according to instrument’s development. In ventricu-
lar and paraventricular tumors, endoscopic biopsy has been less invasive and
safer standard surgery. Here, we report our technique to resect intraventric-
ular tumors with endoscopy. PATIENTS AND METHODS: Between 2007
and 2012, 40 patients with intraventricular tumors have been received endo-
scopic treatment. Our endoscopic system constitutes MINOP Modular
Neuroendoscopy System (Aesculap), VISERA Pro video system with HD
camera (OLYMPUS) and Navigation system (BrainLAB). Approach to
lateral ventricle is performed through frontal craniotomy, in 3 cm diameter.
The field exchange technique is composed of the dry field with evacuated CSF
and the wet field with artificial CSF filled in. RESULTS: Tumor resection was
accomplished in 12 patients. 2 patients received twice endoscopic opera-
tions. There were 2 total resection, 4 subtotal resections and 8 partial resec-
tions. There was no severe complications associated endoscopic resection of
the tumors. CONCLUSION: In the dry field, it is possible to surgical proce-
dures, which are difficult in the wet field. The field exchange technique is nec-
essary in the situation during endoscopic management. Compared to tumor
removal with microscope, however, there are difficult handlings in endoscop-
ic tumor resection, which may be resolved by instruments.
ST-007. ORBITAL METASTASES AS PRIMARY CLINICAL
MANIFESTATION OF LUNG CANCER: CASE REPORT AND
LITERATURE REVIEW
Maria Blagia, Maurizio Paulis, Giuseppe Orunesu, and Salvatore Serra;
Department of Neurosurgery, San Francisco Hospital, Nuoro, Sardinia, Italy
INTRODUCTION: Orbital metastases are an infrequent etiology of adult
proptosis; approximately 3–7% of orbital biopsies have demonstrated a
metastatic tumour, and this diagnosis is often unexpected. Between 2% and
5% of cancer patients will develop an ocular or orbital metastasis. In 25%
of these, it is the presenting sign of malignancy. Frequently, this presents a di-
agnostic challenge and represents a poor prognosis. METHODS: A
50-year-old man presented with swelling of the eyelid margin, local pain
and ptosis of his right eye. Past medical history was unremarkable and the
patient took no medications. A CT scan revealed extensive bony destruction
of the orbital roof and anterior skull base. A right fronto- orbital approach
was used for total removal of the osteolytic tumor. RESULTS: A simple
thorax x-ray reveals atelectasia on the lower left lobe and via a bronchoscopy
we found an endobronchial mass. Weobtained a biopsyand the resulting diag-
nosis was a spinocellular carcinoma, confirming that this is the originating
tumor for the orbital metastasis. Histopathological and cytological study con-
firmed the diagnosis of an orbital metastases associated with abscess.
Postoperative MRI demostrate a total removal of the tumour. Three months
after surgery the patient’s condition is deteriorating and currently is receiving
palliative care. CONCLUSIONS: Any patient with proptosis and/or
ptosis with a history of cancer should be evaluated for orbital metastasis.
Prognosis can be poor, and thus treatment is sometimes palliative in nature, in-
tending to slow the progression of the disease instead of providing a cure.
ST-009. miR-21 IN THE EXTRACELLULAR VESICLES (EVS) OF
CEREBROSPINAL FLUID (CSF): A PLATFORM FOR
GLIOBLASTOMA BIOMARKER DEVELOPMENT
Johnny Akers1, Valya Ramakrishnan1, Ryan Kim1, Johan Skog5,
Ichiro Nakano2, Sandeep Pingle1, Juliya Kalinina4, Santosh Kesari1,
Xandra Breakfield3, Fred Hochberg3, Erwin Van Meir4, Bob Carter1, and
Clark Chen1; 1University of California San Diego, La Jolla, CA, USA; 2Ohio
State University, Columbus, OH, USA; 3Massachusetts General Hospital,
Boston, MA, USA; 4Emory University, Atlanta, GA, USA; 5Exosome
Diagnostics, New York, NY, USA
Glioblastoma cells secrete extra-cellular vesicles (EVs) containing
microRNAs (miRNAs). Analysis of these EV miRNAs in the bio-fluids of af-
flicted patients represents a potential platform for biomarker development.
However, the analytic algorithm for quantitative assessment of EV miRNA
remains under-developed. Here, we demonstrate that the reference transcripts
commonly used for quantitative PCR (including GAPDH, 18S rRNA, and
hsa-miR-103) were unreliable for assessing EV miRNA. In this context, we
quantitated EV miRNA in absolute terms and normalized this value to the
input EV number. Using this method, we examined the abundance of
miR-21, a highly over-expressed miRNA in glioblastomas, in EVs. In a
panel of glioblastoma cell lines, the cellular levels of miR-21 correlated with
EV miR-21 levels (p , 0.05), suggesting that glioblastoma cells actively
secrete EVs containing miR-21. Consistent with this hypothesis, the CSF EV
miR-21 levels of glioblastoma patients (n ¼ 13) were, on average, ten-fold
higher than levels in EVs isolated from the CSF of non-oncologic patients
(n ¼ 13, p , 0.001). Notably, none of the glioblastoma CSF harbored EV
miR-21 level below 0.25 copies per EV in this cohort. Using this cut-off
value, we were able to prospectively distinguish CSF derived from glioblasto-
ma and non-oncologic patients in an independent cohort of twenty-nine pa-
tients (Sensitivity ¼ 87%; Specificity ¼ 93%; AUC ¼ 0.91, p , 0.01). Our
results suggest thatCSF EV miRNA analysis of miR-21 mayserveas aplatform
for glioblastoma biomarker development.
ST-010. ROLE OF SURGERY IN PATIENTS WITH
INTRACRANIAL NON GERMINOMATOUS GERM CELL
TUMORS (NGGCT) TREATED ACCORDING TO SIOP CNS GCT
96 PROTOCOL WITH RESPECT TO THE SITE AND TIME OF
RESECTION
Thomas Czech1, James Nicholson2, Didier Frappaz3, Rolf-Dieter Kortmann4,
Claire Alapetite5, Maria-Luisa Garré6, Umberto Ricardi7, Frank Saran8, and
Gabriele Calaminus9; 1Medical University Vienna, Vienna, Austria;
2Addenbrookes Hospital, Cambridge, UK; 3Centre Léon Bérard, Lyon,
France; 4Medical University, Leipzig, Germany; 5Institut Curie, Paris, France;
6Gaslini Children’s Hospital, Genova, Italy; 7Medical University, Torino,
Italy; 8Royal Marsden Hospital, London, UK; 9Medical University, Münster,
Germany
BACKGROUND:DatafromSIOPCNS GCT 96 andother trials suggest im-
proved outcome with delayed resection of residual tumour in patients with in-
tracranial NGGCTs. The relevance of tumor site on this management
algorithm has not been evaluated. METHODS: Until 31.05.2012, 200 pa-
tients with NGGCT were treated according to SIOP CNS GCT 96. Median
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age was 12 years (range 0-30yrs), 150 were boys. Primary tumour site was
pineal in 107 and suprasellar in 51 patients. A bifocal tumour was present in
20 patients, and in 22 patients there was another primary tumour site. We an-
alyzed the impact of resective surgery in relationship to the tumour site, pineal
vs sellar-suprasellar. RESULTS: In pineal tumours 54/107 had histology at
diagnosis with either upfront resection (36/54) or biopsy (18/54). 53/107
had diagnosis by markers only. Of 20 patients with an upfront gross-total re-
section 7 had an event. Second-look surgery was performed in 29 patients, 4 of
these 29 patients had an event. An event occurred in 28/46 patients with resid-
ual tumour after chemotherapy who did not undergo second-look surgery
prior to radiotherapy. In suprasellar tumours 26/51 had histologyat diagnosis
with 21/26 resective and 5/26 biopsy procedures. Marker-only diagnosis was
done in 25/51 patients. Of 4 patients with primary gross-total resection 1 had
an event. Second-look surgery was done in 7 patients, 2/7 had an event. An
event occurred in 6/31 patients with residual tumour who did not undergo
second-look surgery. CONCLUSION: While second-look surgery seems to
improve outcome in NGGCT primarily located in the pineal region, the
impact of this strategy is less clear in hypophyseo-hypothalamic tumours
and an attempt at second -look gross total resection needs to be weighted
against potentially harmful side-effects.
ST-011. RESECTION PROBABILISTIC MAPS FOR QUALITY
ASSESSMENT OF GLIOMA SURGERY: A COMPARISON OF TWO
SURGICAL CENTERS USING INTRAOPERATIVE STIMULATION
MAPPING
Philip De Witt Hamer1, Eef Hendriks1, Emmanuel Mandonnet2,
Frederik Barkhof3, Koos Zwinderman4, and Hugues Duffau5; 1Neurosurgical
Center Amsterdam, VU University Medical Center, Amsterdam, The
Netherlands; 2Department of neurosurgery, Hôpital de Lariboisière, Paris,
The Netherlands; 3Department of Radiology and Image Analysis Center, VU
University Medical Center, Amsterdam, The Netherlands; 4Department of
Clinical Epidemiology, Biostatistics, and Bioinformatics, Academic Medical
Center, University of Amsterdam, Amsterdam, The Netherlands;
5Department of Neurosurgery, Hôpital Gui de Chauliac, CHU Montpellier,
Montpellier, The Netherlands
BACKGROUND: Intraoperative brain stimulation mapping reduces per-
manent postoperative deficits and extends tumor removal in resective
surgery for glioma patients. Successful functional mapping is assumed to
depend on the expertise of the surgical team. In this study, the extent of
glioma resection (EOR) is quantified using a novel approach, so-called resec-
tion probability maps (RPM), exemplified by a surgical team comparison,
here with long and short experience in mapping. METHODS: Adult patients
with glioma were consecutively included by two centers with two and fifteen
years of mapping experience. Resective surgery was targeted at non-enhanced
MRI extension and was limited by functional boundaries. Neurological
outcome was compared. To compare EOR, we applied RPMs to quantify
and compare the likelihood of resection throughout the brain.
Considerations for spatial dependence of voxels and multiple comparisons
were taken into account. RESULTS: The senior surgical team contributed
56, and the junior team 52 consecutive patients. The patient cohorts were com-
parable in age, preoperative tumor volume, lateralization, and lobe localiza-
tion. Neurological outcome was similar between teams. The probability of
resection on the RPMs was very similar, with none (0%) of 703,967 voxels
in left-sided tumors being differentially resected, and 124 (0.02%) of
644,153 voxels in right-sided tumors. CONCLUSION: RPMs provide a quan-
titative volumetric method to compare EOR, which we present as standard for
quality assessment of resective glioma surgery. Stimulation mapping is a robust
surgical technique, because both the EOR and the neurological outcome are in-
dependent of surgical experience, supporting wider implementation.
ST-012. MANAGEMENT AND OUTCOMES IN PATIENTS WITH
GLIOMA-ASSOCIATED EPILEPSY
Yoshua Esquenazi, Jessica Johnson, and Nitin Tandon; Vivian L. Smith
Department of Neurosurgery, University of Texas, Houston Medical School,
Houston, TX, USA
INTRODUCTION: Seizures are the most frequent presenting symptom in
patients with low-grade tumors and are more prevalent when the lesion is
located in or around the temporal lobe. Resection strategies in these patients
vary between lesionectomy and epilepsy operations with no clear consensus
on optimal approaches. METHODS: A prospectively compiled database of
epilepsy and tumor patients was used to identify patients who underwent sur-
gical resection of a glial neoplasm but then developed epilepsy, or who
presented with epilepsy and were found to harbor a low grade neoplasm.
Seizure frequency, histology, type of surgical resection and outcomes were
compiled. RESULTS: Of 235 patients that underwent cranial procedures for
epilepsy and 79 patients with low/intermediate grade gliomas, 14 (6%) and
20 (25%) respectively had tumoral epilepsy. Etiology was WHO grade 1
gliomas (DNET, Gangliogliomas, JPA) in 33%, grade 2 gliomas in 36% and
grade 3 in 30%. One epilepsy patient had a PNET. Median age was 37 years
(22 male). Most common locations were temporal - 44% (7 lateral, 5 mesial
and 3 extending to insular cortex) and peri-rolandic - 27% (SMA in 5;
lateral in 4). In the epilepsy group, following lesionectomy in 3 and tailored re-
sections in the majority, seizure outcomes were Engel class one in all (1A-10,
1B-2) except for one (class 3). In the tumor group 7 additional resections
were performed due to seizure recurrence – all related to residual or recurrent
tumor after initial surgery. Outcomes were 1A in 18, 1B, 1C and 2A in 1 each.
CONCLUSION: We used an aggressive surgical intervention targeting the
lesion except where medial temporal structures were involved, where a
typical temporal lobectomy was performed. The excellent outcomes (Engel
1 in 94%) relate to aggressive initial tumor resection and re-resection in the
context of recurrence
ST-013. SUPRA-MAXIMAL RESECTIONS FOR NEWLY
DIAGNOSED GLIOBLASTOMA MULTIFORME
Yoshua Esquenazi1, Elliiot Friedman2, Yi Lin1, Jay-Jiguang Zhu1, and
Nitin Tandon1; 1Vivian L. Smith Department of Neurosurgery, University of
Texas Health Science Center at Houston, Medical School., Houston, TX,
USA; 2Department of Radiology University of Texas Health Science Center at
Houston, Medical School., Houston, TX, USA
INTRODUCTION: Despite recent advances, the median overall survival
for patients with GBM remains , 2 years. A substantial body of evidence sug-
gests that cyto-reductive surgery is essential forprolonging survival in these pa-
tients. A “supra-maximal” resection, using sub-pial techniques for low-grade
gliomas may allow for the eradication of proximate nonfunctional, tissue with
high degree of infiltration by glioma cells beyond the zone of contrast enhance-
ment and may result in improved outcomes. The purpose of this study is to
evaluate the safety, feasibility and any addition survival benefit of this tech-
nique in patients with GBM. METHODS: We retrospectively evaluated 79
consecutive patients (2005-2011) operated on for primary GBM with (45)
or without (34) carmustine wafer implantation and adjuvant Stupp protocol
therapy. Presenting clinical, radiological and outcome data were collected.
RESULTS: Median age was 56 years, median KPS was 80 and median preop-
erative tumor volume was 33 cm3. Median follow-up was 15 months. GTR,
NTR, and STR were achieved in 21, 11 and 47 patients respectively, and in
21, 9 and 27 patients within the intent-to-treat population. Median survival
for the whole group was 15 months, and 34.2, 16.5 and 12 months for
GTR,NTRandSTR respectively.Twotransientand twopermanentneurolog-
ical complications related to surgery occurred. Multivariate regression re-
vealed that intraoperative mapping and % residual tumor were the only
predictors of survival. CONCLUSION: The sub-pial technique is safe, effec-
tive and associated with an overall survival benefit not previously seen in
other similar GBM series in which a GTR is achieved. The benefits of the ad-
dition of intra-cavitary carmustine wafer placement may be potentiated with
the supra-maximal resections. Neurological deficits and complications were
favorable compared to other series and did not prevent adjuvant therapy.
ST-014. STEREOTACTIC BIOPSY FOR DEEP SEATED BRAIN
TUMORS USING THE LEKSELL STEREOTACTIC FRAME
SYSTEM
Takamitsu Fujimaki1,2, Masahito Kobayashi1, Kenji Wakiya1, Miki Ohta1,
Junichi Adachi2, Kohei Fukuoka2, Tomonari Suzuki2, Takaaki Yanagisawa2,
Masao Matsutani2, Kazuhiko Mishima2, Jun Sasaki1, and Ryo Nishikawa2;
1Saitama Medical University Hospital, Moroyama, Japan; 2Saitama Medical
Univresity, Internationa Medical Center, Hidaka, Japan
PURPOSE: To evaluate the results of stereotactic biopsy for deep seated
intraaxial lesions. PATIENTS AND METHODS: Sixteen patients with intra-
axial lesions suspected of brain tumor. The locations of lesions were, deep
white matter of cerebrum 4, basal ganglia 1, thalamus 6, midbrain 2, pons
3. Patients age range was 9 -81 years (median 61 years), and 9 were men and
7 were women. Under local anesthesia the Leksell stereotactic frame was
fixed and the MRI were taken. To determine the targets, neuroimages such
as enhanced CT scan or PET study were also used as references. After image
acquisition patients were transferred to OR and under general anesthesia,
several samples were taken with 2.1mm diameter needle by aspiration. Most
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of the cases the biopsy was done through frontal lobe, but in some cases
through temporal lobe or through cerebellum. The samples were taken
deeper and nearer regions of the designed targets with same trajectory, also.
If there were cysts, aspiration of the cyst was performed as much as possible.
The trajectory should avoid sulci, cortical veins or ventricular system. After
biopsy inside the needle were irrigated repeatedly with 0.1 - 0.2 ml saline
using thin plastic tube to ensure hemostasis. RESULTS: In all patients appro-
priate samples for pathological diagnosis were obtained. The diagnoses were
11 gliomas (pilocytic 1, grade II 3, grade III 3, grade VI (GBM) 2, high grade
1, glial tumor 1) 3 lymphomas, 1 germinoma and 1 multiple sclerosis. There
were no symptomatic bleeding nor neurological complications.
CONCLUSION: With detailed planning, stereotactic biopsy was safely per-
formed even from brainstem. Trajectories other than from frontal can be
also considered for lesions. Repeated irrigation with saline might effective to
prevent symptomatic bleeding.
ST-015. SPECIFIC TREATMENT CONSIDERATIONS AND
OUTCOME DATA IN ELDERLY GLIOMA PATIENTS - A SINGLE
CENTER EXPERIENCE
Markus Hoffermann, Lukas Bruckmann, Kariem Mahdy Ali,
Martin Asslaber, Franz Payer, and Gord von Campe; Medical University of
Graz, Graz, Austria
BACKGROUND: Although High Grade Gliomas (HGG) are significantly
more frequent in patients older than 65 years of age, most clinical studies so
far have excluded the elderly population. It is well known that age itself is an
independent risk factor in glioma patients and individualized treatment is
mandatory, given the prevalence of comorbidities in the elderly. Recent mul-
ticenter clinical trials have tried to define the role of different adjuvant thera-
pies, but the role of surgery, especially regarding extent of resection, remains
a matter of lively discussion. MATERIALS AND METHODS: A retrospective
clinical data analysis of 150 patients (90M, 60F) over 65 years with supraten-
torial gliomas (WHO-IV:137, WHO-III:11, WHO-II:2) was performed, with
emphasis on survival data, adjuvant therapies and neurosurgical intervention.
RESULTS: Mean progression free survival was 6.8 months and mean overall
survival (OS) was 8.6 months. In 156 surgical procedures (GTR:43, STR:32,
PR:37, biopsies:30, reoperations:14) we experienced a mortality rate of
3.3% and morbidity of 18.3%, highest in STR. In the High Grade Glioma sub-
group, GTR and STR led to significantly improved median OS compared to
PR, biopsy or no surgical procedure (15 and 12 months vs. 4, 4 and 2
months; p ¼ 0,000). Reoperations were performed in selected cases of HGG
(n ¼ 10) and these patients showed significantly higher OS (21 vs. 7 months
median OS, p ¼ 0,035). Regarding mean OS, adjuvant therapy according to
the STUPP-protocol proved to be more efficient (21.4 months, p ¼ 0,000)
than radio- or chemotherapy alone (5.3 and 8.6), concomitant chemoradio-
therapy (6.5) or best supportive care (3.4) but not significantly different
from radiotherapy followed by chemotherapy (18.6 months, p ¼ 0,94).
CONCLUSION: Our single center experience provides helpful information
on the value of neurosurgical treatment and its impact on outcome in elderly
glioma patients, despite limitations regarding treatment heterogeneity. It sup-
ports the need for further prospective studies in this age group.
ST-016. COMPLETE, BUT NOT PARTIAL RESECTION OF
RECURRENT GLIOBLASTOMA PROLONGS SURVIVAL AFTER
RELAPSE WITHOUT IMPAIRMENT OF FUNCTIONAL
OUTCOME
Christine Jungk, Bernhard Beigel, Vitali Abb, Christel Herold-Mende, and
Andreas Unterberg; Department of Neurosurgery, University Hospital
Heidelberg, Heidelberg, Germany
OBJECTIVE: Standard of care in newly diagnosed glioblastoma (GBM) is
maximal safe tumor resection followed by radio (RT)- and chemotherapy
(CHT). At tumor relapse, however, standard of care, particularly the value
of re-resection, is still under debate. We addressed the significance of recurrent
GBM surgery with regards to functional outcome and survival and special at-
tention paid to the extent of resection (EOR). METHODS: 30 patients were
identified from our tumor database, diagnosed with GBM between 2005
and 2010, having been re-resected at least once for tumor relapse and deceased
at the time of analysis. Patient demographics, functional status, adjuvant ther-
apies and survival times were extracted from medical charts. EOR was deter-
mined on postoperative MRI scans where available. Survival after re-resection
(SRR) was calculated by log-rank test. RESULTS: At initial diagnosis, patients
were treated by complete (CR) or partial resection (PR) followed by radio-/
chemotherapy. 93% of patients received one, 7% two re-resections. Only
10% were treated with second-line RT or CHT prior to re-resection. At 1st
re-resection, CR was achieved in 53%, PR in 40%, EOR could not be deter-
mined in 7%. Incidence of permanent neurologic deterioration did not in-
crease from initial surgery to re-resection (10% vs. 13,3%). Analyzing
patients with CR (n ¼ 16) and PR (n ¼ 12) at re-resection only, both groups
were comparable with respect to demographic data, tumor eloquence, KPS,
number of re-resections and adjuvant therapies for tumor relapse.
Importantly, SRR was significantly prolonged in completely resected patients
(11 vs. 5 months; p ¼ 0,0348) while the rate of permanent deficits was compa-
rable. CONCLUSION: In this analysis, complete resection of recurrent GBM,
compared to PR, was associated with a significantly prolonged SRR without
additional neurologic impairment. These findings stress the significance of
maximal tumor resection even at the time of relapse. Certainly, larger
studies are warranted to confirm these findings.
ST-017. COMPARATIVE STUDY OF LONG-TERM RESULTS FOR
INTRACRANIAL MENINGEAL HEMANGIOPERICYTOMA AND
MALIGNANT MENINGIOMA IN SINGLE INSTITUTION:
FOCUSED IN SURVIVAL AND LOCAL CONTROL
Jeong Hoon Kim, Young Hyun Cho, and Chang Jin Kim; Asan Medical
Center, Seoul, Republic of Korea
INTRODUCTION: Both hemangiopericytoma (HPC) and malignant me-
ningioma (MM) are a rare tumorof meningeal origin that behaves aggressively
with a high rate of local recurrence and distant metastases. Two diseases are
clinically very similar but there are no comparative study for long term
outcome between HPC and MM. Therefore, we present our experiences.
MATERIAL AND METHODS: We retrospectively reviewed pathologically
proven 30 patients of HPC and 39 patients of MM treated from 1991 to
2006 with at least 5 years follow-up period. Data including clinical character-
istics, treatment modalities, recurrence and survival were reviewed. Statistical
analysiswasdone with regards to overall survival (OS) and recurrence free sur-
vival (RFS) using Kaplan-Meier survival analysis. RESULTS: The median age
at presentation of HPC and MM was 43.0 and 52.0 years. Twenty seven of 30
(90%) in HPC and 28 of 39 (72%) in MM underwent complete resection
(Simpson Grade 1 and 2). The 3-, 5-, and 10-year overall survival rates of
HPC were 100%, 100%, and 43%, and those of MM were 87%, 64%, and
32%, respectively. The 3-, 5-, and 10-year recurrent rates of HPC were
23%, 40%, and 56% and those of MM were 47%, 49% and 75%.
Adjuvant radiotherapy (RT) after surgical resection was an important signifi-
cant prognostic factor for OS and RFS (p ¼ 0.026, p ¼ 0.024), but complete
resection was not in HPC (p ¼ 0.565, p ¼ 0.228). In contrast, complete resec-
tion was important prognostic factor for OS and RFS (p ¼ 0.004, 0.047) al-
though adjuvant RT was not significant factor in MM (p ¼ 0.432, p ¼
0.742). CONCLUSION: We conclude that both HPC and MM are very ag-
gressive tumor with high recurrent and low survival rate. While complete re-
section is best treatment modality in MM, surgical resection with adjuvant
RT is best treatment modality in HPC. Long-term and meticulous follow-up
is mandatory for local recurrences and distant metastases.
ST-018. MRI-BASED HIGH RESOLUTION MAPS FOR
PLANNING/GUIDING HIGH PRECISION PROCEDURES IN
BRAIN TUMOR PATIENTS
Yael Mardor1,2, Ouzi Nissim1, Yuval Grober1, David Guez1, David Last1,
Dianne Daniels1,2, Chen Hoffmann1,2, Dvora Nass1, Alisa Talianski1,
Roberto Spiegelmann1,2, Zvi Cohen1,2, and Leor Zach1,2; 1Sheba Medical
Center, Ramat Gan, Israel; 2Tel Aviv University, Tel Aviv, Israel
BACKGROUND: Conventional MRI is currently unable to differentiate
tumor from non-tumoral tissues (such as radionecrosis). We have applied
delayed contrast extravasation MRI for calculating high resolution maps
clearly differentiating tumor from non-tumoral tissues. Here we demonstrate
the application for improved targeting of high precision procedures.
METHODS: 33 patientswith primary/metastatic brain tumors post chemora-
diation/radiosurgery were scanned by delayed contrast extravasation MRI
prior to surgery. High resolution maps were calculated from T1-MRI acquired
2 and 75 min post contrast injection. 44 stereotactic biopsies planned using the
maps were acquired from 17 patients, En-block samples were acquired from 3
and gross total samples were acquired from 13. Histological assessment was
then compared with the pre-surgical maps for all patients. RESULTS: The
maps showed two primary populations: the delayed contrast accumulation
population (red in the maps) and the delayed contrast clearance population
(blue). In all cases, samples obtained from blue regions in the maps consisted
of morphologically active tumor while samples obtained from red regions
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consisted of non-tumoral tissues. According to our maps, in this cohort of pa-
tients 52.4+1.9% (on average) of the enhancing volume on T1-MRI did not
represent morphologically active tumor. CONCLUSIONS: The fact that
50% of the enhancing volume on T1-MRI represents non-tumoral tissues
emphasizes the need for improved targeting of high precision procedures.
The excellent correlation between our pre-surgical maps and histology sug-
gests that the maps may be applied for planning of diagnostic stereotactic bi-
opsies, high precision surgeries and focused-radiation treatments (SRS,
iMRT) thus significantly improving targeting to regions of morphologically
active tumor. Our recent technological development provides 3D maps of
1 mm3 resolution, providing increased sensitivity to small regions of active
tumor. In addition, the 3D maps are naturally registered to the standard
FSPGR navigation sequence, thus may be easily loaded onto the
NeuroNavigation system for straight-forward application.
ST-019. LONG-TERM OUTCOMES OF PATIENTS UNDERGOING
AGGRESSIVE SURGICAL MANAGEMENT OF INSULAR TUMORS
Neena Marupudi and Sandeep Mittal; Wayne State University - Detroit
Medical Center, Detroit, MI, USA
INTRODUCTION: Aggressive surgical resection of insular tumors is neu-
rosurgically challenging due to anatomically and functionally complex corti-
cal structure of the insula. The effects of insular neoplasms on surrounding
architecture further complicate resection. Some advocate stereotactic biopsy
followed by radiotherapy. However, we demonstrate that aggressive surgical
management of insular tumors can be achieved with minimal morbidity
using specialized microsurgical techniques. METHODS: We performed a ret-
rospective review of all patients undergoing surgical resection for insular
tumors at our institution since 2006 (n ¼ 12). Follow-up ranged from
3-months to 6-years (median ¼ 3-years). Each patient underwent circumfer-
ential microsurgical dissection and en bloc insular tumor removal. All proce-
dures were performed by a single neurosurgeon. The surgical procedure
included skeletinization of insular branches of the middle cerebral artery
and preservation of perforators (lenticulostriate arteries). Patients presenting
with intractable seizures underwent Wada test and PET imaging prior to
surgery. Postoperatively, surgical outcomes were characterized by the follow-
ing: 1) histological diagnosis, 2) controlof seizures, 3) extent of tumor removal
4) development of new neurological deficits, and 5) long-term outcomes.
RESULTS: Nine patients had insular tumors histologically classified as
gliomas; remaining lesions included metastases and primary CNS lymphoma.
All patients underwent gross total resection. No patient had persistent motor
or speech deficit on long-term postoperative follow-up. All patients with re-
fractory seizures (n ¼ 5) had good seizure control from the comprehensive re-
section. Low-grade gliomas involving the insular lobe remain confined. Due to
the expansile growth of insular gliomas, the lenticulostriate vessels are exten-
sively shifted and displaced medially. Insular gliomas demonstrate a stereo-
typic sharp border medially, which initially aids in creating the plane of
resection. CONCLUSION: Our neurosurgical technique optimizes volumet-
ric resection of insular tumors with preservation of surrounding neurovascular
structures, preventing long-term neurologic morbidity. With new technical re-
finements in imaging and neuronavigation, radical removal of insular tumors
is feasible with minimal morbidity.
ST-020. FRAME-BASED OR FRAMELESS STEREOTACTIC
BIOPSY: THE DEBATE CONTINUES
Karine Michaud, Léo Cantin, Sylvine Cottin, and Charlotte Dandurand; CHU
de Québec, Quebec City, QC, Canada
Two different systems are available for stereotactic biopsy of cerebral
lesions; frame-based and frameless. Multiple studies have shown that the
safety and diagnostic accuracy of both systems are equivalent. Yet, most neu-
rosurgeons, depending on their personal experience or preference, use one
system preferentially. We reviewed the cases done at our institution between
2000 and 2013 and seeked any differences or biases toward one system or
the other. 469 biopsies were done; 289 frame-based and 180 frameless. The
2 groups were matched for age (mean 56.3), sex (59% male), comorbidities,
symptoms at presentation, radiographic appearance and localisation of the
lesion (deep 21%) and maximal diameter of the lesion (4.4mm). The patients
undergoing frame-based bipsoy did so under local anesthesia (83.7%) as
opposed to patients undergoing frameless biopsy (92.2% general anesthesia).
There were no more morbidities associated with general anesthesia. The surgi-
cal time was longer, although not significantly, for the frameless biopsies (p ¼
0.08). Hemorrhagic complications occuring during the surgery were more fre-
quent for the frame-based system (21.1% vs 12.8%, p ¼ 0.02). Post-biopsy
hemorrhage as seen on the post-op CT scan was more frequent in the frameless
group (36.7% vs 25.6%, p ¼ 0.001), although this could be accounted for by
the fact that the frame-based patients underwent their CT scan sooner after the
surgery compared to the frameless group (13.1% vs 9.3%). The diagnostic ac-
curacy of both techniques were similar, with only 1% of blank biopsies in each
group. This study, which is one of the largest in the litterature, confirms the
equivalent safety and diagnostic accuracy of both techniques. Although
there were more hemorrhages during the frame-based procedures, the rate of
neurologic complications were similar as were the lengths of stay at the hospi-
tal. The study also confirms that both techniques are suitable for deep-seated
lesions.
ST-021. LASER INTERSTITIAL THERMAL THERAPY (LITT) AS A
TREATMENT MODALITY FOR DIFFICULT-TO-ACCESS HIGH
GRADE GLIOMAS: A MULTI-CENTER STUDY
Alireza Mohammadi1, Ammar Hawasli2, Analiz Rodriguez3, Jason Schroeder1,
Adrian Laxton3, Paul Elson1, Stephen Tatter3, Gene Barnett1, and
Eric Leuthardt2; 1Cleveland Clinic, Cleveland, OH, USA; 2Washington
University, St. Louis, MO, USA; 3Wake Forest University, Winston-Salem, NC,
USA
INTRODUCTION: Surgical extent-of-resection has been shown to have an
impact in high grade glioma (HGG) outcomes, but it is rarely achievable in
difficult-to-access (DTA) tumors. Controlled thermal damage to the tumor
may have the same impact in DTA-HGGs. We report our multi-center
results of Laser Interstitial Thermal Therapy (LITT) in DTA-HGGs.
METHODS: We retrospectively reviewed 35 consecutive DTA-HGG patients
(24 GBM, 11 anaplastic gliomas) who underwent LITT in the Cleveland
Clinic, Washington University, and Wake Forest University during 5/
11-12/12. LITT was performed under MR-thermography guidance using
NeuroBlate device (Monteris, Winnipeg). Extent of thermal damage was de-
termined as thermal-damage-threshold (TDT) lines including: yellow
TDT-line ¼ 438C for 2 minutes and blue TDT-line ¼ 438C for 10 minutes.
Pre- and post-operative MRI scans as well as TDT-lines were imported into
the iPlan software (BrainLAB, Germany) for volumetric analysis. Extent of
coverage (EOC) by TDT-lines and residual tumor volume (RTV) uncovered
by TDT-lines were measured. Patient outcomes were evaluated statistically.
RESULTS: Median age was 56 years and 40% were female. Treatment was
upfront in 19 and salvage in 16 patients. Median tumor volume was 10.1cc
(0.7-49cc). One patient died because of meningitis and 7 patients had neuro-
logical worsening after procedure (temporary in 5 patients). After a median
of 7.2 months follow-up, 80% of patients have progressed and 34% died.
Median overall-survival was not reached (1-year overall survival is estimated
to be 68% + 9%). Median progression-free-survival (PFS) was 5.1 months.
Thirteen patients who had both .99% EOC by yellow TDT-line and
,1.5cc RTV uncovered by blue TDT-line had better PFS than others (9.7
versus 4.6 months; p ¼ 0.02) which was still prognostic in the subgroup of
24 GBM patients (p ¼ 0.04). CONCLUSIONS: LITT can be used safely and
effectively for treatment of DTA-HGGs. More complete coverage of tumor
by TDT-lines improves PFS which can be translated as the extent of resection
concept for surgery.
ST-022. USE OF 5-AMINOLEVULINIC ACID FOR DETECTION OF
RESIDUAL MENINGIOMA FOR TOTAL REMOVAL AND
AVOIDANCE OF NEUROLOGICAL DEFICITS
Shusuke Moriuchi1, Makoto Dehara1, Takanori Fukunaga1,
Yasushi Hagiwara1, Hakao Soda2, and Masami Imakita3; 1Department of
Neurosurgery, Rinku General Medical Center, Izumisano, Osaka, Japan;
2Department of Neurology, Rinku General Medical Center, Izumisano,
Osaka, Japan; 3Department of Pathology, Rinku General Medical Center,
Izumisano, Osaka, Japan
5-Aminolevulinic acid (5-ALA) has been used successfully to resect menin-
gioma without residual mass. The authors report their experience in the resec-
tions of 15 patients with meningioma using 5-ALA. Except one case, all
meningiomas fluoresced intraoperatively under microscope. Invasions to the
dura mater, the brain parenchyma or skull fluoresced, allowing for confirma-
tion of residual tumor and total removal of the meningioma could perform
more easily and prevent unexpected neurological deficit by precise removal
of the tumor under microscope. In a case with invasions to dura mater or
skull, the extent of dural removal was decided by 5-ALA fluorescence with
1-2 cm safty margins. In another case with parenchymal invasions, close
removal of the tumor without residual tumor could be performed with
5-ALA fluorescence. With the above methods, no serious side effects or
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complications occurred in this study. Not all of meningiomas fluoresced with
5-ALA, and 5-ALA is available for about 90% of meningiomas. 5-ALA would
be easy to use and be useful to find residual tumor and also useful to prevent
recurrences by total removal in meningiomas.
ST-023. UPDATED THERAPEUTIC STRATEGY FOR ADULT
LOW-GRADE GLIOMA STRATIFIED BY RESECTION,
HISTOLOGY, AND MOLECULAR MARKERS
Masayuki Nitta1,2, Takashi Maruyama1,2, Hiroshi Iseki1,2, Soko Ikuta2,
Manabu Tamura2, Mikhail Chernov2, Saori Okamoto1, Yoshikazu Okada1,
and Yoshihiro Muragaki1,2; 1Department of Neurosurgery, Neurological
Institute, Tokyo Women’s Medical University, Tokyo, Japan; 2Institute of
Advanced Biomedical Engineering & Science, Tokyo Women’s Medical
University, Tokyo, Japan
BACKGROUND: There is no established standard therapy for adult low-
grade glioma (LGG), and there is a large difference in therapeutic strategy
between institutes. Based on the outcome of ten years in our institute, we
have recently established our updated therapeutic strategies for LGG.
METHODS: We retrospectively analyzed of 153 patients (mean age; 39 yo,
56 male, 44 female) with LGG who underwent surgical treatment between
2000 and 2010. Pathological subtypes were as follows: 49 diffuse astrocytoma
(DA), 45 oligoastrocytoma (OA), 59 oligodendroglioma (O). Patients with
≥95% EOR were observed and others were treated with radiation and/or che-
motherapy. RESULTS: Median preoperative tumor volume was 29.0cm3 and
median EOR was 95%. 10-year OS and 5-year PFS for all the patients were
95.1% and 60.2%, respectively. Eight-year OS for DA, OA and O were
70.9%, 91.2%, and 98.3%, respectively. Both OS and PFS were significantly
longer in patients with ≥90% EOR than those with ,90% EOR (P , 0.01).
Increased EOR resulted in better PFS for diffuse astrocytoma (P , 0.01) but
not for oligodendroglioma. Multivariate analysis identified age (HR ¼ 4.08;
95% CI, 1.08-16.96; P ¼ 0.038) and EOR (HR ¼ 4.75; 95% CI, 0.7-26.48;
P ¼ 0.039) asparameters significantlyassociatedwith OS.Theonlyparameter
associated with PFS was EOR (HR ¼ 2.69, 95% CI, 1.43-5.04; P ¼ 0.002).
Chemotherapy prolonged PFS in patients with oligodendroglilal subtypes
(P ¼ 0.006). However, there was no survival benefit of radiation and chemo-
therapy in diffuse astrocytoma. CONCLUSIONS: Our updated therapeutic
strategy for LGG is followings; 1. Patients with ≥90% EOR are carefully ob-
served without any adjuvant therapy regardless of tumor subtype. 2. DA pa-
tients with ,90% EOR are considered second look resection and if
impossible, radiotherapyand nimustine hydrochloride (ACNU) based chemo-
therapy are conducted. 3. OA and O patients with ,90% EOR and
co-deletion of 1p19q loci are treated with ACNU and the others are treated
with both radiotherapy and ACNU.
ST-024. SURGERY USING A TRACTOGRAPHY-INTEGRATED
NAVIGATION SYSTEM AND MOTOR EVOKED POTENTIALS
FOR PRESERVATION OF MOTOR FUNCTION IN PATIENTS
WITH MALIGNANT GLIOMA
Shiro Ohue, Shohei Kohno, Akihiro Inoue, Daisuke Yamashita,
Yoshiaki Kumon, and Takanori Ohnishi; Department of Neurosurgery,
Ehime University Graduate School of Medicine, Toon, Ehime, Japan
INTRODUCTION: The optimal surgery for malignant gliomas, at present,
is maximal tumor resection without deterioration of neurological function.
We evaluated the contribution of using tractography-integrated navigation
system and motor evoked potentials (MEPs) to surgical and functional out-
comes. METHODS: Subjects comprised 50 patients who underwent resection
for malignant glioma near the pyramidal tract (PT) in our hospital. Diffusion
tensor imaging (DTI) was performed using a 3-T magnetic resonance scanner,
and DTI-based tractography of the PT was loaded into the navigation system
for intraoperative guidance. If possible, silicone catheters as fence posts were
inserted along the tumor boundaries, avoiding the course of the PT before
removal. Cortical MEPs were monitored intermittently during resection.
When the line of resection closely approached the PT, subcortical MEPs
were used to identify proximity to the PT by observing motor responses.
When a response was elicited, removal was abandoned to ensure preservation
of the motor function. RESULTS: DTI-based tractography of the PTs was per-
formed successfully in all patients. Fence post techniques using a
tractography-integrated navigation system were applied in 46 patients. This
fence post technique was useful to clarify the resection plane before resection,
and to resect the tumors safely and easily. Amplitudes of cortical MEPs after
tumor resection were 30-140% of those obtained before resection. Although
no subcortical MEPs were observed at 20-mA stimulus intensity in eight
patients throughout tumor resection, the other 42 patients showed obvious re-
sponses of subcortical MEPs at ≤20 mA. The degree of resection was total in
22 patients, subtotal in 15, and partial in 13. At one month postoperatively,
only one patient showed worsened motor function because of tumor progres-
sion. CONCLUSION: A tractography-integrated navigation system and
MEPs are useful for preserving motor function during tumor resection in pa-
tients with malignant gliomas near the PT.
ST-025. 5-ALA GUIDED RESECTION OF MALIGNANT GLIOMA:
A SINGLE INSTITUTION EXPERIENCE
Pierandrea Oppido, Veronica Villani, Antonello Vidiri, Andrea Pace,
Alfredo Pompili, and Carmine Carapella; Regina Elena National Cancer
Institute, Roma, Italy
INTRODUCTION: Malignant glioma represent a relevant therapeutic
issue and the value of extensive surgical resection remains debated; recent ev-
idence suggests that radical removal is associated with better survival. An in-
teresting tool for identifying tumor tissue and increasing the extent of
surgery is represented by fluorescence-guided resection, taking advantage of
metabolic and structural changes induced by 5-amino-levulinic acid (ALA),
a natural precursor of heme biosynthetic pathway. METHODS: The present
experience is related to 48 patients affected by malignant glioma (28 newly
diagnosed and 20 recurrent tumors): 42 glioblastoma (GBM), 4 anaplastic
oligodendroglioma, 1 oligodendroglioma I WHO and 1 pleomorphic xan-
thoastocytoma. All patients underwent preoperative and early postoperative
MRI, showing contrast enhancing lesions. All patients were selected for
fluorescence-guided resection. An oral dose of 20 mg 5-ALA /kg bw was ad-
ministered to each patient. Microsurgical resection was performed by an oper-
ating microscope enabled to visualize the fluorescence. All the patients, as first
line treatment, have been submitted to radiotherapy and chemotherapy;
second and in some cases third line treatments were utilized in recurrent
cases.RESULTS: Inmore than90%ofpatients tumor tissue showed intraoper-
ative red fluorescence; mainly in recurrent GBM, when MRI documented het-
erogeneous lesions with enhancing areas mixed with gliotic scars,
fluorescence-guided surgery allowed a better definition of active tissue, with
net margins from perilesional “healthy” brain. Early postoperative MRI con-
firmedgross total resection in80%of thepatients. In the present experience the
procedure did not determine any relevant additional neurological deficit.
Considering overall survival of recurrent patients we obtained a median
extension of at least 9.0 months (4 – 16+ months). CONCLUSIONS:
Fluorescence-guided surgery improves tumor detection and allows extended
resection of malignant glioma, without any relevant impact on neurological
status, resulting helpful mainly in the recurrent setting with a consistent
effect on overall survival.
ST-026. THE PROGNOSTIC SIGNIFICANCE OF EXTENT OF
RESECTION AND RESIDUAL VOLUME IN GLIOBLASTOMA
PATIENTS
Daniel Orringer, Darryl Lau, and Yashar Niknafs; University of Michigan,
Ann Arbor, MI, USA
INTRODUCTION: Conflicting evidence exists on the importance of
maximal resection in glioblastoma patients. Furthermore, the mechanism by
which resection prolongs survival remains unclear. We hypothesize that
maximal resection is most beneficial in patients where gross total resection is
feasible and that surgical resection confers benefits to glioblastoma patients
through both brain decompression (assessed by extent of resection) and a re-
duction in the volume of viable tumor (assessed by residual tumor volume).
METHODS: A consecutive population of patients who underwent cranioto-
my for GBM resection from 2005-2011 were identified. FIJI image analysis
software was used to perform volumetric analysis of pre- and post-operative
MRIs todetermine tumor volume,EOR andRV.Resectabilitywasdetermined
with a published grading scheme that is based on tumor location relative to
brain function. Statistical comparison of survival by EOR, and RV was per-
formed via log-rank test and Kaplan Meir curves. RESULTS: Sixty-five pa-
tients had sufficient images for analysis. Overall 1-year survival was
61.5%. Greater EOR (p , 0.001) was associated with higher 1-year survival
rates: in patients where EOR was greater than 90%, 1-year survival was
85.3%. Higher RV was significantly associated with poorer survival (p ¼
0.012): when RV was greater than 8,000 mm^3, the 1-year survival rate
was 35.0%. When RV was less than 8,000 mm^3, 1-year survival rates
were in excess of 80%. EOR and RV were found to be significant predictors
of survival in patients with resectable tumors (p , 0.001 and p ¼ 0.044, re-
spectively). However, EOR and RV were not predictive of survival in patients
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with non-resectable tumors (p ¼ 0.399 and p ¼ 0.356, respectively).
CONCLUSION: Maximal safe resection likely provides a greater benefit
to glioblastoma patients with resectable tumors than to those with non-
resectable tumors. Surgical resection may confer a survival benefit by de-
creasing the degree of compression on the brain and by reducing the
volume of viable tumor.
ST-027. FLUORESCENCE GUIDE SURGERY IN HIGH GRADE
GLIOMAS USING A HIGH-DEFINITION EXOSCOPE SYSTEM: AN
ALTERNATIVE TO MICROSCOPE
Jose Piquer, Jose Luis Llacer, Vicente Rovira, Pedro Riesgo, and
Antonio Cremades; Hospital Univesitario de la Ribera,Alzira.Valencia, Spain
INTRODUCTION: Fluorescence-guided microsurgical resections of high-
grade gliomas using 5-aminolevulinic acid (5-ALA) have proved to be superior
to conventional microsurgery. An optical device, usually a modified micro-
scope, is needed for these procedures. However, an exoscope may be imple-
mented for fluorescence techniques. OBJECTIVE: We present the use of an
exoscope to perform tumor resection guided by 5-ALA fluorescence in 21
consecutive patients with high-grade glioma and 2 neuronavigation
guided biopsy. METHODS: Twenty-five three were operated using
ALA-fluorescence implemented in an exoscope system. Tumor volume and lo-
calization were quantified with pre- and postoperative volumetric magnetic
resonance imaging in non biopsy cases. RESULTS: In non biopsy cases the
age range in our series was 20 to 79 years, with a median of 56 (interquartile
range ¼ 45-66). Histological analysis indicated that 14 had glioblastoma mul-
tiforme,2grade-III oligodendrogliomaand1anaplasticastrocytoma, 3metas-
tases and 1 low grade astrocytoma. Total resection was achieved in 15 cases,
subtotal resection was performed in 5 patients, and in one case, the result
wasapartial resection.Therewasnoperioperativemortality.The medianfluo-
rescence intensity, on a scale of 1-5, was 4.5 in the GBM group (IQR ¼ 4-5), 3
(IQR ¼ 2.5-3.5) in the cases of anaplastic glioma and 2.5 (IQR ¼ 2.25-2.75)
for the oligodendrogliomas. Of the three metastases, one showed a level 4
degree of fluorescence. In the two biopsy cases, 1 was an anaplastic astrocyto-
ma and 1 a glioblastoma multiforme. In both cases the samples obtained from
tumor were fluorescence. CONCLUSIONS: An exoscope can be also used to
for fluorescence-guided surgery and with 5-aminolevulinic acid (5-ALA) and
neuronavigation guided biopsy. With an important advantage of low cost
allows the surgeon to perform collaborative surgeries and adds agility to the
procedure.
ST-028. PREOPERATIVE nTMS GENERATED MOTOR AND
LANGUAGE MAPS: FEASIBILITY AND OUTCOME
Roger Rotta, Nicholas Levine, Sujit Prabhu, Raymond Sawaya,
Jeffrey Weinberg, Ganesh Rao, Sudhakar Tummala, and Catherine Tilley;
University of Texas MD Anderson Cancer Center, Houston, TX, USA
INTRODUCTION: The management of brain tumors adjacent to speech
and motor areas presents a surgical challenge. The goals are maximal safe re-
section and preservation of neurological function. Pre-surgical functional in-
formation about the cortical and subcortical areas at risk is crucial for the
avoidance of neurological deficits during tumor surgery. Intraoperatively
direct electrical stimulation (DES) is the "gold standard" to identify and pre-
serve essential function. Recently nTMS has been shown to be useful in gener-
ating both motor and speech maps prior to surgery. METHODS: We describe
our 23 consecutive patients with brain tumors located adjacent to eloquent
areas (motor and language). All cases were performed with nTMS, intraoper-
ative DES and awake craniotomy during language mapping. RESULTS: Of the
23 patients 84% were HGG (grade III and IV), 4% LGG (grade II), 4% Grade I
and 20% Metastasis. Parietal lobe was the most frequent location of tumors
seen in 13 (56%) cases. In 95% of patients a positive response in upper extrem-
ity (UE) nTMS, correlated wellwith those generatedby DES (94%). In 4(23%)
cases nTMS was superior to DES in isolating the lower extremity (LE) re-
sponse. Of the 6 (25%) cases performed for speech mapping, 1(17%) case
had a true positive response and 1(17%) a false positive while true negative
was seen in 4(66%). A gross total resection (GTR) was achieved in 14
(61%) patients, and at 1 month follow-up, 18(78%) had no deficit, 4
(18%) stable and 1(4%) worsening. There were no adverse events during
the stimulation. CONCLUSION: Navigated transcranial magnetic stimula-
tion can be safely used in pre-surgical mapping of the motor cortex involving
both the UE and LE and the results correlate well with DES. Despite a 66%
rate of true negative response in speech mapping, nTMS helped understand
the functional cortical organization preoperatively and facilitated successful
resection.
ST-029. MINIMALLY INVASIVE SURGICAL RESECTION OF
SUBCORTICAL TUMORS USING THE SIX PILLARS SYSTEM
Richard Rovin1 and Amin Kassam2; 1Marquette General Hospital,
Marquette, MI, USA; 2The Ottawa Hospital, Ottawa, ON, Canada
The neurological cost of access to subcortical tumors often precludes surgi-
cal removal, thus denying these patientsabiologicallymeaningful intervention
available to their counterparts with more superficially located lesions. By inte-
grating the latest technologies from mapping, image guidance, access, optics,
resection and therapeutic platforms, the Six Pillars System optimizes the min-
imally invasive approach to deep tumors. At the heart of the system is the FDA
approvedBrainPathdevice—a13.5 mmtubular retractor that isdirected to the
tumor via a trans-sulcal trajectory designed to minimize shear force to the in-
tervening white matter fiber tracts. The first surgeries in the United States using
the Six Pillars System were performed atMarquette General Hospital. Todate,
17 patients with tumor have been treated. There were six men and eleven
women. Five patients harbored primary tumors (two glioblastoma and three
grade III astrocytoma). Twelve patients had metastatic tumors. Following
surgery, five patients improved neurologically, nine were unchanged, and
one patient had a persisting deficit. Two patients had postoperative seizure.
No patient developed a postoperative infection. One patient expired, one
month after surgery. The average length of stay for patients treated with the
Six Pillars System was 2.25 days, compared to 4.82 days for patients undergo-
ing open craniotomy. The authors conclude that the minimally invasive ap-
proach to subcortical tumors using the Six Pillars System is safe and effective
for appropriately selected patients.
ST-030. LOW-DOSE RATE IODINE-125 BRACHYTHERAPY IN
RECURRENT MALIGNANT GLIOMAS
Christoph Schwartz1, Alexander Romagna1, Niklas Thon1,
Jörg-Christian Tonn1, Silke Birgit Schwarz2, and Friedrich-Wilhelm Kreth1;
1Department of Neurosurgery, Munich, Bavaria, Germany; 2Department of
Radio-Oncology, Munich, Bavaria, Germany
OBJECTIVE: Prognosis of recurrent malignant gliomas (WHO III and IV) is
dismal and despite numerous efforts postrecurrent survival (PRS) remains
short. This pivotal study evaluates the effectiveness and treatment-associated
risks of low-dose rate Iodine-125 stereotactic brachytherapy (SBT) in highly
selected patients with circumscribed tumor recurrence. METHODS: Data of
patients with treatment between 2003 and 2011 were prospectively collected
and retrospectively analyzed. Indications for SBT were histologically verified
recurrent gliomas WHO III or IV with a diameter of ,4cm based on MRI
and 18FET-PET, and a KPS of ≥70%. Biomarker status included MGMT-
methylation, IDH1/2 mutations, LOH 1p/19q. SBT was performed via tem-
porary iodine-125 seed implantation. Reference dose was 50 Gy, dose rates
were low (, 15 cGy/h). Date of last follow-up (FU) was 02/2012. Survival
analysis was performed with the Kaplan-Meier method. RESULTS: 71 pa-
tients (35 males, 36 females) were included. Median age at seed implantation
was 52 years, the median KPS was 90%. All patients had received prior treat-
ment. Histological diagnoses included 41 glioblastomas WHO IV, 20 astrocy-
tomas WHO III, 9 oligoastrocytomas WHO III, and 1 oligodendroglioma
WHO III. The median tumor volume was 2.5 cm3 and the median treatment
time was 450 hours. The median FU was 34 months. Median PRS after SBT
was 9.5 months (CI95% 7.6-18.4) and 25.7 months (CI95% 11.5-42.3) for
WHO IV and III tumors. Favorable prognostic factors for PRS after SBT
were patient age at SBT (p ¼ 0.002) and LOH 1p/19q (p ¼ 0.04). Neither
tumor grade, nor MGMT-methylation, nor IDH1/2 mutations had anysignif-
icant impact. Transient morbidity was seen in 17% of patients, no permanent
morbidity was found. CONCLUSIONS: Low-dose rate Iodine-125 SBT is an
attractive additive local treatment option for highly-selected patients with re-
current malignant gliomas who had previously undergone multimodal
therapy. SBT efficacy is seemingly independent from MGMT-methylation
and IDH 1/2 mutation status.
ST-031. THE ROLE OF SURGERY FOR ANAPLASTIC GLIOMAS
WITH IDH GENE MUTATION
Yukihiko Sonoda1, Ichiyo Shibahara1, Ryuta Saito1, Masayuki Kanamori1,
ToshihiroKumabe2, andTeijiTominaga1; 1TohokuUniversity, Sendai, Japan;
2Kitasato University, Sagamihara, Japan
INTRODUCTION: IDH gene mutation was frequently found in anaplastic
gliomas. Although IDH gene mutation has been reported to be a favorable
prognostic factor, anaplastic gliomas with IDH gene mutations sometimes re-
curred as secondary glioblastoma. In this study, we investigated the role of
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surgery for anaplastic gliomas with IDH gene mutation. METHODS: We an-
alyzed clinical (extent of resection), genetic (1p19q codeletion, TP53 gene mu-
tation) factors for correlation with progression free survival (PFS) and overall
survival (OS). RESULTS: Eighty-one patients with IDH mutant anaplastic
gliomas were investigated. Thirty patients received total resection on MRI.
Median PFS was 187 months and median OS was not reached. Eighteen of
50 patients received less than subtotal resection recurred during follow-up
period (median PFS 74 months). 12 of 18 tumors had TP53 gene mutations
and other 6 tumors had 1p19q co-deletion. On the other hand, tumor recur-
rence was observed in only four patients which underwent total resection.
Three of those also had TP53 gene mutation. Overall survival of total resection
group and non-total resection group were not reached and 136 months respec-
tively (p ¼ 0.0036). 10 years survival rate of total resection group and non-
total resection group were 93.4% and 50.4% respectively. CONCLUSION:
Patients of anaplastic gliomas with IDH mutation had favorable prognosis.
Particularly, total resection was significantly associated with survival. Even
in patients with IDH mutant gliomas, TP53 gene mutation still had risk for
recurrence.
ST-032. PHENYTOIN REDUCES 5-ALA MEDIATED
FLUORESCENCE IN GLIOBLASTOMA CELLS
Christopher Steele1,3, Johnathan Lawrence1,3, Richard Rovin2,3, and
Robert Winn1,3; 1Northern Michigan Univeristy, Marquette, MI, USA;
2Marquette General Hosptial, Marquette, MI, USA; 3Upper Michigan Brain
Tumor Center, Marquette, MI, USA
Glioblastoma multiforme (GBM) is a devastating form of cancer, and essen-
tially all GBM tumors recur causing fatality. A new surgical technique,
fluorescence-guided resection of GBM using 5-aminolevulinic acid (5-ala), im-
proves the extent of resection and positively impacts the length and quality of
patient survival. The fluorescence achieved in neoplastic tissue depends
directly on the accumulation of porphyrins derived from the metabolism of
the 5-ala prodrug within the cancer cell. However, 5-ala induced fluorescence
has been reported to be inconsistent. In an effort to determine the cause of the
inconsistent fluorescence, the authors investigated the effect of medications
commonly prescribed to brain tumor patients on 5-ala induced fluorescence.
A model was developed to quantify intracellular porphyrin accumulation
using a U87MG GBM cell line constitutively expressing yellow fluorescent
protein (YFP-U87). 5-ala mediated fluorescence within the cells was standard-
ized to cell number via the fluorescence emission spectra ratio of porphyrin
(405 nm) to YFP (525 nm). 5-ala induced accumulation of porphyrins was
measured after treating YFP-U87 cells with phenytoin, dexamethasone, or
desipramine for 3 days. After a 6 hour incubation with 5-ala, no significant dif-
ference in porphyrin accumulation was observed in cells treated with dexame-
thasone or desipramine. Phenytoin, however, significantly reduced the
accumulation of fluorescent porphyrins within the YFP-U87 cell line by
nearly 30% compared to the control. To optimize fluorescence during
surgery and improve patient survival these results suggest that further investi-
gationsarewarranted todetermine the effects of commonlyadministeredmed-
ications on 5-ala fluorescence-guided resection of GBM.
ST-033. MALE GENDER IS A RISK FACTOR FOR THE CLINICAL
COURSE OF SKULL-BASE CHORDOMAS
Walter Rachinger1, Matthias Simon2, Stephan Dützmann3, Günther Feigl4,
Natalia Kremenevskaya5, Niklas Thon1, and Jörg-Christian Tonn1;
1Department of Neurosurgery, Munich, Germany; 2Department of
Neurosurgery, Bonn, Germany; 3Department of Neurosurgery, Frankfurt,
Germany; 4Department of Neurosurgery, Tübingen, Germany; 5Department
of Neurosurgery, Erlangen, Germany
OBJECTIVE: Chordomas of the skull base are rare, locally invasive and
have a poor prognosis. Recently, the expression ratio of the transmembrane
cell adhesion proteins N-cadherin and E-cadherin has been suggested to
provideadditional prognostic information.Aim of this retrospective multicen-
tric confirmatory study was to evaluate prognostic factors including expres-
sion of N- and E-cadherins in patients initially treated with microsurgical
tumor resection. METHODS: 47 patients (21 women, 26 men, mean age 49
years) treated in five academic centers were included. Histology was centrally
reviewed, aswell asN-andE-cadherin-expressionby immuno-histochemistry.
Prognostic factorswereobtained frommultivariate regressionmodels. Forsur-
vival analysis the Kaplan-Meier method was used. RESULTS: The median
follow-up period was 5.2 years. Gross total resection, subtotal resection and
extended biopsy were done in 14.9%, 80.9%, and 4.2%, respectively.
Adjuvant radiotherapy (including proton beam irradiation) was applied in
63.8% of the patients. Median progression free survival was 7.3 years.
Multivariate analysis identified male gender as an independent risk factor
for tumor progression (p ¼ 0.04) and death (p ¼ 0.03), despite the fact that
radical resection was achieved more often in males (p ¼ 0.036). Neither ex-
pression rates of E-cadherin and N-cadherin nor their ratio did gain prognostic
influence. None of the other patient-, tumor- or treatment related prognostic
factors (age, duration of symptoms, Karnofsky score, extent of resection, ad-
juvant radiotherapy) proved to be of prognostic relevance in the multivariate
model. CONCLUSION: In skull base chordomas, male patients bear a signifi-
cantly higher risk of recurrency and death. Expression of E- and N-cadherin
has no prognostic significance. These data might help to identify high risk pa-
tients in whom more aggressive adjuvant therapy or at least a closer follow-up
schedule is warranted. Moreover, further studies are needed to elucidate the
potential mechanism of gender disparity with regard to tumor progression
and prognosis.
ST-034. PHOTODYNAMIC THERAPY OF BRAIN TUMORS
Harry Whelan, Mike Kelly, Sachin Jogel, Bruce Kaufmann, Andy Foy,
Sean Lew, and Brendan Quirk; Medical College of Wisconsin, Milwaukee,
WI, USA
Weconductedahumanbrain tumor PDTstudythatevaluated the toxicityof
PDT based on both light-emitting diode (LED) and laser technology in selected
patientswith recurrent/progressivebrain tumors. Twopatientsdisplayed neu-
rotoxicity, one after laser treatment using an interstitial fiber directly inserted
into the tumor, one with the laser-balloon adapter combination. Escalating
doses of Photofrinw were tolerated to the maximum dose of 2.0 mg kg-1.
Light dose was 100 J/cm + 2. PDT in the posterior fossa or near eloquent
brain was tolerated using the LED or laser-balloon adapter. All patients had
tumor responses as documented by MRI scan and the mean time to tumor pro-
gression after PDT was 67 weeks. Eight were pediatric patients, all of whom
received Photofrinw, who exhibited relapse-free survival times ranging from
8 weeks to 13 years. None showed neurotoxicity. Of the 20 patients, four
had tumors in the posterior fossa area, with one developing a significant neu-
rological deficit. This patient was one of the two using interstitial fiber illumi-
nation. 111In-Photofrinw was determined using external imaging and
quantitation with a gamma camera. 99mTC-DTPA was used as a control for
nonspecific uptake. Specific tumor uptake of the 111In-Photofrinw occurred
well beyond that resulting from blood-brain-barrier breakdown. A phase 1
study is being performed on pediatric patients with supra or infratentorial
primary brain tumors who undergo neurosurgery at the Children’s Hospital
of Wisconsin in Milwaukee. A minimum of 12 study subjects will be used
with four different photofrin dose levels: 0.5 mg/kg, 1.3 mg/kg, 2.0kg/mg,
and 3.0 mg/kg. Photoactivation of Photofrinw is controlled by the total
light dose delivered over the treatment time. PDT lasers are equipped with a
calibration unit to calibrate the fibers and yield the required power density
output (mW) necessary to deliver a light dose of 240 J/cm + 2.
ST-035. RE-OPERATION FOR RECURRENT GLIOBLASTOMA
MULTIFORME
Raymund L. Yong1,3, Tianxia Wu1, Nino Mihatov1, Michael J. Shen1,
M.Anthony Brown1,KareemA. Zaghloul1,Grace E.Park2, and JohnK. Park1;
1National Institute of Neurological Disorders and Stroke, Bethesda, MD,
USA; 2National Human Genome Research Institute, Bethesda, MD, USA;
3Mount Sinai School of Medicine, New York, NY, USA
BACKGROUND: The standard of care for patients with newly diagnosed
gliblastoma multiforme (GBM) is surgical resection followed by radiation
and temozolomide chemotherapy. Treatment regimens at the time of
tumor recurrence, which occurs in virtually all patients, have not been stan-
dardized and repeat surgical resection (re-operation) is considered in only
one in four patients. METHODS: This retrospective study comprised 97 con-
secutive patients who were deemed favorable candidates for re-operation on
the basis of previously validated prognostic criteria. Multivariate analyses
were carried out to identify pre- and post-operative clinical and radiographic
variables independently associated with overall survival after re-operation.
Volumetric area under the curve (AUC) analysis of 619 serial post-operative
magnetic resonance imaging (MRI) studies (median 4 per patient) was per-
formed to determine the regrowth rate of tumors following re-operation.
RESULTS: The median post-operative survival of all patients following
re-operation was 12.4 months (95% CI, 9.0–15.6). In a multivariate
analysis, progressively larger post-operative residual tumor volume was
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independently associated with decreased survival (p , 0.001), along with
greater age (p ¼ 0.003) and lower pre-operative Karnofsky performance
status (KPS) (p , 0.001). Larger volume residual tumors had higher rates
of subsequent regrowth (p ¼ 0.003), and a higher regrowth rate in turn
independently associated with decreased survival (p , 0.001).
CONCLUSIONS: The median survival of patients re-operated for recurrent
GBM compares favorably to historical controls. Re-operation should be con-
sidered in all patients who meet favorable pre-operative clinical and radio-
graphic criteria. For patients undergoing re-operation, the surgical goal
should be to leave a minimal amount of residual tumor tissue in order to
slow tumor regrowth and maximize survival benefit.
Abstract
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